Galactosylceramides (Galactocerebrosides)

Cerebrosides which contain as their polar head group a galactose moiety bound in glycosidic linkage to the hydroxyl group of ceramide. Their accumulation in tissue, due to a defect in beta-galactosidase, is the cause of galactosylceramide lipidosis or globoid cell leukodystrophy.

Also Known As:

Networked: 380 relevant articles (21 outcomes, 48 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hermans, Ian F: 9 articles (01/2022 - 05/2012)
2.	Porcelli, Steven A: 9 articles (01/2021 - 02/2011)
3.	Trottein, François: 9 articles (01/2020 - 10/2011)
4.	Painter, Gavin F: 7 articles (01/2022 - 11/2014)
5.	Weinkove, Robert: 7 articles (01/2022 - 12/2012)
6.	Besra, Gurdyal S: 7 articles (01/2021 - 09/2010)
7.	Motohashi, Shinichiro: 7 articles (01/2020 - 11/2010)
8.	Nakayama, Toshinori: 6 articles (01/2020 - 11/2010)
9.	Faveeuw, Christelle: 6 articles (01/2017 - 10/2011)
10.	Fontaine, Josette: 6 articles (01/2017 - 10/2011)

Related Diseases

1.	Neoplasms (Cancer) 02/01/2011 - "Furthermore, the ability of β-mannosylceramide to synergize with α-galactosylceramide suggests treatment with this class of iNKT agonist may provide protection against tumors in humans." 01/01/2023 - "However, clinical trials evaluating administration of iNKT cell-specific agonist α-galactosylceramide (α-GalCer) have failed to achieve obvious tumor regression. " 01/01/2020 - "We conducted a phase I study of the trans-bronchial injection of α-galactosylceramide (αGalCer)-pulsed antigen presenting cells (APCs) to evaluate their safety, immune responses, and anti-tumor activities. " 10/01/2017 - "Therapeutic activation of iNKT cells with α-galactosylceramide (α-GalCer) can prevent and reverse tumor growth in mice and clinical trials involving α-GalCer-stimulated iNKT cells are ongoing in humans. " 01/01/2013 - "In this study, we demonstrate that the interaction of NKDCs and natural killer T (NKT) cells is required for the anti-tumor immune responses that are elicited by α -galactosylceramide ( α -GC) in mice. "
2.	Virus Diseases (Viral Diseases) 01/01/2017 - "Therapeutic treatment with α-Galactosylceramide could further improve the reduction of early retroviral replication by NKT cells, which could be utilized for future treatment against viral infections." 06/01/1999 - "SPC3 inhibited the LAV-2/B-mediated infection of B-cell line which does not express the CD4 and the galactosylceramide molecules on their cell surface, suggesting an SPC3-sensitive CD4/galactosylceramide-independent pathway of viral infection in HIV susceptible cells. " 01/10/2011 - "α-Galactosylceramide (α-GalCer) is a safe and effective adjuvant for nasal vaccines and induces protective immune responses against tumors and viral infections. " 02/01/2011 - "Although iNKT cells and their prototype glycolipid agonist α-galactosylceramide (α-GalCer) have shown promise in several clinical trials conducted in patients with cancer or viral diseases, current iNKT cell-based therapies are far from effective. "
3.	Leukemia 04/01/2015 - "We propose that post-remission vaccination with a simple autologous whole cell vaccine adjuvanted with α-galactosylceramide may be effective to prevent relapse of acute leukemia." 11/06/2014 - "The murine acute leukemia model C1498 was used to study the efficacy of an intravenously administered vaccine consisting of irradiated leukemia cells loaded with the natural killer T (NKT)-cell agonist α-galactosylceramide (α-GalCer). " 01/01/2021 - "Here, we investigated the effects of reducing the dose of PTCy followed by α-galactosylceramide (α-GC), a ligand of iNKT cells, on the reciprocal balance between graft-versus-host disease (GVHD) and the graft-versus-leukemia (GVL) effect. "
4.	Lymphoma (Lymphomas) 12/15/2013 - "Furthermore, we show that a combination of vorinostat with α-galactosylceramide (α-GalCer), an IFN-γ-inducing agent, was significantly more potent against established lymphoma than vorinostat treatment alone. " 01/01/2014 - "Using the EL4 T-lymphoma cell line as a model, we found that iNKT cells exert robust and specific lysis of tumor cells in vitro in a manner that is differentially induced by iNKT cell agonists of varying T-cell receptor (TCR) affinities, such as OCH, α-galactosyl ceramide, and PBS44. " 11/16/2017 - "In a delayed-treatment, aggressive, murine model of A20 B lymphoma that mimics human diffuse large B cell lymphoma, we show that therapeutic A20 lysate vaccine adjuvanted with an NKT cell agonist, α-galactosylceramide (α-GalCer), provides long-term immune protection against lethal tumor challenges and the antitumor immunity is primarily CD8 T cell dependent. " 01/01/2020 - "Materials & methods: Vaccines were prepared by either loading the NKT cell agonist, α-galactosylceramide onto irradiated and heat-shocked B- and T-lymphoma cells, or chemically conjugating α-galactosylceramide to MHC-binding peptides from a lymphoma-associated antigen. " 11/01/2013 - "Among them, a natural killer T cell (NKT)-ligand, α-galactosylceramide (αGC) has been reported as a powerful adjuvant showing therapeutic effects in solid tumors as well as hematological malignancies including lymphoma. "
5.	Colonic Neoplasms (Colon Cancer) 01/01/2016 - "Co-operation of α-galactosylceramide-loaded tumour cells and TLR9 agonists induce potent anti-tumour responses in a murine colon cancer model." 01/01/2020 - "Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer." 01/01/2023 - "Enhanced antitumor efficacy of mesenchymal stem cells expressing cytosine deaminase and 5-fluorocytosine combined with α-galactosylceramide in a colon cancer model." 01/01/2023 - "In this study, we investigated the combined therapeutic effects of mesenchymal stem cells expressing cytosine deaminase (MSC/CD) and 5-fluorocytosine (5-FC) with α-galactosylceramide (α-GalCer) in a colon cancer model. " 04/01/2018 - "The aim of the present study was to investigate the effects of 5-fluorouracil (5-Fu) and oxaliplatin on the function and activation pathways of mouse dendritic cells (DCs), and to clarify whether 5-Fu/oxaliplatin combined with the CD1d-MC38/α-galactosylceramide (α-GC) tumor vaccine exhibits synergistic effects on the treatment of colon cancer in mice. "

Related Drugs and Biologics

1.	Vaccines
2.	Ligands
3.	Glycolipids
4.	Peptides (Polypeptides)
5.	Cytosine Deaminase
6.	Flucytosine (Ancobon)
7.	Glycosphingolipids
8.	Interferons
9.	DNA (Deoxyribonucleic Acid)
10.	Interleukin-17 (Interleukin 17)

Related Therapies and Procedures

1.	Therapeutics
2.	Immunotherapy
3.	Treatment Delay
4.	Intraperitoneal Injections
5.	Radiotherapy